Cargando…
Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
Hematopoietic cell transplantation from haploidentical donors (haploHCT) has facilitated treatment of AML and MDS by increasing donor availability and became more feasible since the introduction of post-transplant cyclophosphamide (ptCY). In our single-center retrospective analysis including 213 pat...
Autores principales: | Rieger, Max J., Stolz, Sebastian M., Müller, Antonia M., Schwotzer, Rahel, Nair, Gayathri, Schneidawind, Dominik, Manz, Markus G., Schanz, Urs |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555825/ https://www.ncbi.nlm.nih.gov/pubmed/37479752 http://dx.doi.org/10.1038/s41409-023-02042-z |
Ejemplares similares
-
New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020) -
Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
por: Kanda-Kato, Madoka, et al.
Publicado: (2020) -
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022) -
Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update
por: Patel, Dilan A., et al.
Publicado: (2020) -
Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years
por: Hofer, Kevin D., et al.
Publicado: (2022)